Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
about
Good clinical outcomes but high rates of adverse reactions during linezolid therapy for serious infections: a proposed protocol for monitoring therapy in complex patients.Daptomycin-nonsusceptible vancomycin-intermediate staphylococcus aureus vertebral osteomyelitis cases complicated by bacteremia treated with high-dose daptomycin and trimethoprim-sulfamethoxazoleReduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implicationsRelationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infectionsEvolution of multidrug resistance during Staphylococcus aureus infection involves mutation of the essential two component regulator WalKRSynergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic modelBenefits of therapeutic drug monitoring of vancomycin: a systematic review and meta-analysisManagement and Novel Adjuncts of Necrotizing Soft Tissue Infections.A mutation in the PP2C phosphatase gene in a Staphylococcus aureus USA300 clinical isolate with reduced susceptibility to vancomycin and daptomycin.Different bacterial gene expression patterns and attenuated host immune responses are associated with the evolution of low-level vancomycin resistance during persistent methicillin-resistant Staphylococcus aureus bacteraemia.High frequency of linezolid-associated thrombocytopenia and anemia among patients with end-stage renal disease.Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patientsPractical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience.pH-Dependent Antimicrobial Properties of Copper Oxide Nanoparticles in Staphylococcus aureus.Phenotypic and genotypic characteristics of persistent methicillin-resistant Staphylococcus aureus bacteremia in vitro and in an experimental endocarditis model.Necrosis of Staphylococcus aureus by the Electrospun Fe- and Ag-Doped TiO2 Nanofibers.Phosphorylation of MgrA and its effect on expression of the NorA and NorB efflux pumps of Staphylococcus aureus.USA600 (ST45) methicillin-resistant Staphylococcus aureus bloodstream infections in urban DetroitPrevention, diagnosis, therapy and follow-up care of sepsis: 1st revision of S-2k guidelines of the German Sepsis Society (Deutsche Sepsis-Gesellschaft e.V. (DSG)) and the German Interdisciplinary Association of Intensive Care and Emergency MedicineQuantitative determination of telavancin in pregnant baboon plasma by solid-phase extraction and LC-ESI-MS.Evaluation of vancomycin population susceptibility analysis profile as a predictor of outcomes for patients with infective endocarditis due to methicillin-resistant Staphylococcus aureus.The impact of vancomycin susceptibility on treatment outcomes among patients with methicillin resistant Staphylococcus aureus bacteremia.Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.General principles of antimicrobial therapy.Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.Vancomycin pharmacokinetics and pharmacodynamics during short daily hemodialysisDumb and dumber--the potential waste of a useful antistaphylococcal agent: emerging fusidic acid resistance in Staphylococcus aureus.Mitigation of Staphylococcus aureus-mediated surgical site infections with ir photoactivated TiO2 coatings on Ti implants.Therapeutic monitoring of vancomycin according to initial dosing regimen in pediatric patients.Phase 2, randomized, double-blind, dose-ranging study evaluating the safety, tolerability, population pharmacokinetics, and efficacy of oral torezolid phosphate in patients with complicated skin and skin structure infections.Vascular catheter-associated infections: a microbiological and therapeutic update.Tracking the in vivo evolution of multidrug resistance in Staphylococcus aureus by whole-genome sequencing.Mechanisms of antibiotic resistance in Staphylococcus aureus.Linezolid for the treatment of drug-resistant infections.How do we use therapeutic drug monitoring to improve outcomes from severe infections in critically ill patients?Isolates with low-level vancomycin resistance associated with persistent methicillin-resistant Staphylococcus aureus bacteremia.Current and novel antibiotics against resistant Gram-positive bacteriaMethicillin-resistant Staphylococcus aureus in HIV-infected patients.Reversible antibiotic tolerance induced in Staphylococcus aureus by concurrent drug exposure.Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au
P2860
Q24542412-E9DF7CAE-7BCD-4922-AF1E-ED5B7A78FFC8Q24620644-41D79750-BE8C-462F-A01E-C0DBF2E41585Q24646677-62CF4654-7D9F-4F8D-B954-C4DB20B00053Q27011138-34A1D1A9-830B-4FA4-8C0A-10105FDFCC7BQ28477900-90AED73D-08D0-42B6-B509-8B73411C044FQ28481497-1D5E9886-821D-4FB8-B5D9-D5409C2B1C8CQ28534516-74183D52-8BAA-449C-9F92-49DC2FAC23CFQ30234954-ADF3C961-CE7E-48D1-B0C5-CE4D853A9557Q30455758-602DE67F-264A-418C-9CB3-AF271556949CQ33321447-81B307DC-4091-4C3C-A2B0-DF8B73FB0AD6Q33369409-AB1FD06C-9EF5-4B5A-AC4B-5C4DF321F3E8Q33500363-3B732746-D850-46D0-A268-6CB178364E46Q33602468-0B4C0747-9720-4245-9C68-218E2F19EF84Q33624615-0DF0B8A9-E52B-46A6-A824-F923D7035B61Q33683520-5455B657-7DCB-40B8-BCB3-F2932982F741Q33776656-7C904128-25FB-4258-9CF9-CF2D7F7C49ECQ33826193-1FCBB719-DB86-4E3A-A42E-3E15FA1383AEQ33909407-1F9181EE-F744-40C2-92BD-07FBD99A802DQ33974292-85FC800C-4534-41A2-914F-5E9B713787D5Q34022843-CAFAA912-E27D-479E-B634-20F0FF52B46CQ34058222-E9BB6356-5ECC-4BDD-B94D-08D40ECD4826Q34091829-2E7C2D37-B517-44F4-995C-12C333CDAE19Q34157657-DAA1C289-06DF-406E-8BA9-2ACF2C4182CDQ34161745-81EFEBB2-4EDF-43A4-8748-9D1A066FF911Q34402839-DAE383F5-9F94-4CCC-B452-29369C138E54Q34405301-CA89F281-3298-4DB4-BB2B-42FFF694E4F9Q34481625-D4EBD517-9EA4-4793-872A-250498A85620Q34489407-1287E11A-C025-40DB-BF4B-22EAE15BE527Q34494676-3A936E74-EC28-471A-BC1E-F8C189E3D3BDQ34529205-496ACC0D-4352-4CD3-BE7C-AC4FF79B6BA6Q34585059-5C8D26BB-754F-4588-ACA2-DDEC8F7887BBQ34630593-6D09FEE5-85D6-4722-9218-B50C97FD4B61Q34657311-37553296-DA3B-4BBD-B8A1-8629DE052D58Q34894133-187A03FC-1C2B-4F3D-888B-909FC330EF10Q34894900-03BAA71F-6D4E-4A38-9155-A721C9F87880Q35023343-8F9FAE81-A9FC-4FF4-A174-2EA3F333D81BQ35026521-3C35D48B-341D-4AB1-A266-E29CE8915213Q35026548-ED5326B6-EAFB-4980-B24D-922FAA875D07Q35038242-D3DD2655-5E06-4FB0-A12D-843116CD2BEEQ35066896-AD819215-1799-4288-8F31-AA4463B20C4A
P2860
Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@en
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@nl
type
label
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@en
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@nl
prefLabel
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@en
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@nl
P2093
P2860
P50
P356
P1476
Treatment outcomes for serious ...... ced vancomycin susceptibility.
@en
P2093
Andrew Fuller
Arthur J Morris
Barrie C Mayall
Elizabeth A Grabsch
Jenny Robson
Kerry Read
M Lindsay Grayson
Patrick G P Charles
Paul D R Johnson
P2860
P304
P356
10.1086/381202
P407
P577
2004-01-29T00:00:00Z